Cingal® is the only viscosupplement that combines a corticosteroid for fast pain relief with a viscosupplement, a clear gel-like substance containing hyaluronic acid, for sustained osteoarthritis knee pain relief.
A single intra-articular injection of Cingal® can provide rapid* osteoarthritis knee pain relief that’s felt as early as 1 week following the injection and that can last up to
Over time, changes in the synovial fluid and degeneration of joint structures may lead to osteoarthritis knee pain.
Hyaluronic acid is a naturally occurring substance found in the synovial fluid of the knee joint. Viscosupplementation, or the injection of hyaluronic acid into the joint, is thought to lubricate the cartilage (much as oil lubricates an engine), thereby reducing pain for long-term relief with a delayed onset.
Corticosteroid (or cortisone) has anti-inflammatory properties and may be used to relieve pain by reducing swelling in the joint for short-term rapid relief.
Cingal® combines the lubricating effect of hyaluronic acid with the anti-inflammatory properties of a corticosteroid in a single injection.
When you have osteoarthritis, there may not be enough natural hyaluronic acid in the joint, and the quality of that hyaluronic acid may be poorer than normal.
Cingal® is given in a single shot (injection) directly into the knee joint. The injection of Cingal® supplements (adds) hyaluronic acid into the knee joint. The corticosteroid contained in Cingal® quickly reduces inflammation to provide fast relief, while the hyaluronic acid cushions the knee joint to provide long-lasting relief.
If oral painkillers and lifestyle changes such as exercising and losing weight are not providing you with adequate pain relief, Cingal® may be a good option to relieve your osteoarthritis knee pain.
Access our private insurance coverage guide for reimbursement information on Cingal®.
Use our clinic locator to find a specialist near you who can diagnose the cause of your knee pain and guide you through treatment options.
*Significant reduction in pain measures seen at Week 1 vs. saline (ITT p=0.008).